Halla Skuladottir1, Jorgen H Olsen. 1. Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark. halla@cancer.dk
Abstract
PURPOSE: The survival probability of patients with lung cancer is usually based on the extent of disease as assessed at the time of diagnosis. The discouraging 5-year survival is often reported (< 10%) without taking into account changes in the survival probability as time advances from diagnosis. PATIENTS AND METHODS: Conditional survival estimates by sex, age, extent of disease, and histology were estimated for patients diagnosed with lung cancer in Denmark from 1943 to 1997. Survival probabilities were calculated by the Kaplan-Meier method, and cumulative survival estimates were used to derive conditional survival estimates. RESULTS: For every additional year survived, the probability of surviving the next 5 years increases from 33% (men) and 36% (women) after the first year, to 60% (men) and 67% (women) who have survived 5 years. The 5-year survival probability of patients younger than 49 years who had survived the first year was 33%, and increased to 81% after the fifth year. Corresponding estimates for 60- to 69-year-old patients were 23% and 52%. The conditional survival differed greatly among patients with localized and regional disease (29% and 10%, respectively) in the first year, but converged with time (52% and 47%, respectively) after 5 years. The conditional survival is similar in patients with squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma, but is markedly lower in patients with small-cell carcinoma. CONCLUSION: For patients who have survived more than 1 year, the conditional survival probability provides a more accurate estimate of survival as compared with the conventional observed survival rates.
PURPOSE: The survival probability of patients with lung cancer is usually based on the extent of disease as assessed at the time of diagnosis. The discouraging 5-year survival is often reported (< 10%) without taking into account changes in the survival probability as time advances from diagnosis. PATIENTS AND METHODS: Conditional survival estimates by sex, age, extent of disease, and histology were estimated for patients diagnosed with lung cancer in Denmark from 1943 to 1997. Survival probabilities were calculated by the Kaplan-Meier method, and cumulative survival estimates were used to derive conditional survival estimates. RESULTS: For every additional year survived, the probability of surviving the next 5 years increases from 33% (men) and 36% (women) after the first year, to 60% (men) and 67% (women) who have survived 5 years. The 5-year survival probability of patients younger than 49 years who had survived the first year was 33%, and increased to 81% after the fifth year. Corresponding estimates for 60- to 69-year-old patients were 23% and 52%. The conditional survival differed greatly among patients with localized and regional disease (29% and 10%, respectively) in the first year, but converged with time (52% and 47%, respectively) after 5 years. The conditional survival is similar in patients with squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma, but is markedly lower in patients with small-cell carcinoma. CONCLUSION: For patients who have survived more than 1 year, the conditional survival probability provides a more accurate estimate of survival as compared with the conventional observed survival rates.
Authors: Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen Journal: Haematologica Date: 2013-09-13 Impact factor: 9.941
Authors: Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas Journal: Gastric Cancer Date: 2007-09-26 Impact factor: 7.370
Authors: Lauren C Harshman; Wanling Xie; Georg A Bjarnason; Jennifer J Knox; Mary MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Min-Han Tan; Sun-Young Rha; Frede Donskov; Neeraj Agarwal; Christian Kollmannsberger; Scott North; Brian I Rini; Daniel Y C Heng; Toni K Choueiri Journal: Lancet Oncol Date: 2012-08-08 Impact factor: 41.316
Authors: Koji Sasaki; Hagop M Kantarjian; Preetesh Jain; Elias J Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Koichi Takahashi; Naveen Pemmaraju; Naval Daver; Sherry A Pierce; Susan M O'Brien; Jorge E Cortes Journal: Cancer Date: 2015-10-19 Impact factor: 6.860
Authors: Stefan Buettner; Georgios Antonios Margonis; Yuhree Kim; Faiz Gani; Cecilia G Ethun; George A Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2016-08-05 Impact factor: 5.344
Authors: Francesco Alessandro Mistretta; Carlotta Palumbo; Sophie Knipper; Elio Mazzone; Angela Pecoraro; Zhe Tian; Gennaro Musi; Paul Perrotte; Emanuele Montanari; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Ottavio de Cobelli; Pierre I Karakiewicz Journal: World J Urol Date: 2019-07-11 Impact factor: 4.226
Authors: Samuel J Wang; Amanda R Wissel; Join Y Luh; C David Fuller; Jayashree Kalpathy-Cramer; Charles R Thomas Journal: Ann Surg Oncol Date: 2011-01-05 Impact factor: 5.344
Authors: Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik Journal: Ann Surg Date: 2017-01 Impact factor: 12.969